Wells William McDowall 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Dec 8, 2010
Insider Transaction Report
Form 4
Wells William McDowall
DirectorChief Executive Officer
Transactions
- Sale
Common Stock, no par value
2010-12-06$28.13/sh−490,461$13,796,668→ 75,000 total - Sale
Common Stock, no par value
2010-12-07$28.05/sh−17,390$487,790→ 75,000 total - Tax Payment
Common Stock, no par value
2010-12-07$26.12/sh−2,150$56,158→ 92,390 total - Exercise/Conversion
Restricted Share Units
2010-12-07−19,540→ 0 totalFrom: 2010-11-08Exp: 2013-02-17→ Common Stock, no par value (19,540 underlying) - Exercise/Conversion
Common Stock, no par value
2010-12-07+19,540→ 94,540 total
Footnotes (4)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.29, inclusive. The reporting person undertakes to provide to Valeant Pharmaceuticals International, Inc. ("Valeant"), any shareholder of Valeant, or the staff of the Securities and Exchange Commission, in each case upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Common shares withheld from the issuance of common shares to the Reporting Person to satisfy the tax withholding obligations due upon vesting of Restricted Stock Units ("RSUs").
- [F3]Each RSU represents a contingent right to receive one common share, no par value, of Valeant.
- [F4]The RSUs accelerated in connection with the merger between the issuer (formerly known as Biovail Corporation) and Valeant Pharmaceuticals International and vested following the completion of the issuer's blackout period restrictions on November 8, 2010.